EGRX - Eagle Pharmaceuticals up 10% on Q3 beat

Eagle Pharmaceuticals ([[EGRX]] +8.0%) Q3 results:Revenue of $49.93M (+21.3% Y/Y) beats consensus by $2.95M;  reflecting increased product sales of BELRAPZO and RYANODEX, as well as the $5.0M milestone from SymBio, partially offset by lower product sales of BENDEKA.Gross margin rose 1200bps to 76%.Net income of $7.1M, or $0.51/diluted share beats consensus by $0.49 vs. net loss ($2.4M), or ($0.17)/diluted share. Non-GAAP net income of $16.1M, or $1.17/diluted share beats consensus by $0.88 vs. net income $3.7M, or $0.26/diluted share.During Q3, Eagle Pharma repurchased $28M of common stock.In Q3, FDA granted priority review for the Company’s abbreviated new drug application ((ANDA)) filed for vasopressin; trial date set for January 11, 2021.The company, promoted Brian Cahill as Eagle’s new Chief Financial Officer.Japanese licensing partner, SymBio, recieved regulatory approval of its TREAKISYM Ready-to-Dilute formulation from the Pharmaceuticals and Medical Devices Agency in Japan; entitled to receive a $5M milestone payment. SymBio’s conversion of its current lyophilized formulation of TREAKISYM to Eagle’s RTD liquid formulation and commercial launch are expected

For further details see:

Eagle Pharmaceuticals up 10% on Q3 beat